Literature DB >> 32579777

Evolving trends in the prevalence of hepatitis C virus antibody positivity among HIV-infected men in a community-based primary care setting.

Yun-Chi Chen1, Chloe L Thio2, Farin Kamangar1, Andrea L Cox2, Kjell J Wiberg3.   

Abstract

Hepatitis C virus (HCV) infections in the United States occurred mostly among those born between 1945 and 1965. However, new infections continue to increase in recent years. To understand the changes in the prevalence and risk factors of HCV infection in different age and risk groups among men living with HIV, we performed a retrospective cross-sectional analyses of 1948 HIV-infected men at a multisite community health centre in urban/suburban and rural Maryland from 2003 through 2014. We used multivariate logistic regression to determine factors associated with HCV antibody (anti-HCV) positivity and restricted cubic spline method to model trends in anti-HCV prevalence over time. The overall anti-HCV prevalence was 24.2%. The annual prevalence declined in the full cohort, from 38% in 2003 to 24% in 2014, and among those ≥ 40 years old. However, the annual prevalence increased initially and then stabilized in the groups of men who were younger (<40 years old) or had injection-drug use and/or sex with men. Among the younger injection-drug users, the prevalence rose from 33% in 2003 to 79% in 2009 and then stabilized. The independent predictors for anti-HCV positivity differed between the men with and without injection-drug use and between those < 40 and ≥ 40 years old. Notably, a high prevalence of anti-HCV was observed among the younger, white injection-drug users residing in rural areas. Thus, the HCV epidemic continued unabated among high-risk individuals in this diverse population of HIV-infected men. The ongoing HCV transmission among young HIV-infected men poses a challenge en route to HCV eradication.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  HCV; HIV; anti-HCV prevalence; injection-drug use; men who have sex with men

Year:  2020        PMID: 32579777      PMCID: PMC7544680          DOI: 10.1111/jvh.13354

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  45 in total

1.  Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV.

Authors:  Emma C Thomson; Eleni Nastouli; Janice Main; Peter Karayiannis; Joseph Eliahoo; David Muir; Myra O McClure
Journal:  AIDS       Date:  2009-01-02       Impact factor: 4.177

2.  Incidence of Hepatitis C Virus Infection in the Human Immunodeficiency Virus Outpatient Study Cohort, 2000-2013.

Authors:  Taraz Samandari; Ellen Tedaldi; Carl Armon; Rachel Hart; Joan S Chmiel; John T Brooks; Kate Buchacz
Journal:  Open Forum Infect Dis       Date:  2017-06-10       Impact factor: 3.835

Review 3.  Sexually transmitted hepatitis C infection: the evolving epidemic in HIV-positive and HIV-negative MSM.

Authors:  Ian Lockart; Gail V Matthews; Mark Danta
Journal:  Curr Opin Infect Dis       Date:  2019-02       Impact factor: 4.915

4.  Update on the Epidemiology and Prevention of HIV/AIDS in the United States.

Authors:  Amanda D Castel; Manya Magnus; Alan E Greenberg
Journal:  Curr Epidemiol Rep       Date:  2015-06

5.  Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.

Authors:  Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; Chong-Gee Teo; Amy Jewett; Brittney Baack; David B Rein; Nita Patel; Miriam Alter; Anthony Yartel; John W Ward
Journal:  MMWR Recomm Rep       Date:  2012-08-17

6.  Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities.

Authors:  Holly Hagan; Enrique R Pouget; Ian T Williams; Richard L Garfein; Steffanie A Strathdee; Sharon M Hudson; Mary H Latka; Lawrence J Ouellet
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226

7.  Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users.

Authors:  Jennifer R Havens; Michelle R Lofwall; Simon D W Frost; Carrie B Oser; Carl G Leukefeld; Richard A Crosby
Journal:  Am J Public Health       Date:  2012-11-15       Impact factor: 9.308

8.  Prevalence and characteristics of hepatitis C virus coinfection in a human immunodeficiency virus clinical trials group: the Terry Beirn Community Programs for Clinical Research on AIDS.

Authors:  Ellen M Tedaldi; Katherine Huppler Hullsiek; Carlos D Malvestutto; Roberto C Arduino; Evelyn J Fisher; Paul J Gaglio; Elizabeth R Jenny-Avital; Joseph P McGowan; George Perez
Journal:  Clin Infect Dis       Date:  2003-05-06       Impact factor: 9.079

Review 9.  An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection.

Authors:  Arthur Y Kim; Shauna Onofrey; Daniel R Church
Journal:  J Infect Dis       Date:  2013-03       Impact factor: 5.226

10.  Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic.

Authors:  Anouk T Urbanus; Thijs J van de Laar; Ineke G Stolte; Janke Schinkel; Titia Heijman; Roel A Coutinho; Maria Prins
Journal:  AIDS       Date:  2009-07-31       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.